Editorial: Harnessing chemotherapy resistance and development of novel therapeutic strategies for acute leukemia with KMT2A (MLL)-gene rearrangements

Front Pharmacol. 2022 Aug 8:13:977741. doi: 10.3389/fphar.2022.977741. eCollection 2022.

Authors

Maria Teresa Esposito¹, Anna Hagström-Andersson², Ronald W Stam³, Stefania Bortoluzzi⁴

Affiliations

¹ School of Life and Health Science, University of Roehampton, London, United Kingdom.
² Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.
³ Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands.
⁴ Department of Molecular Medicine, University of Padova, Padua, Italy.

No abstract available

Keywords: ALL; AML; KMT2A; Leukemia; MLL; drug repositioining.

Publication types

Editorial